Market Overview

VEGA Group Issues Short Report On GW Pharma; Expert Calls Thesis 'Flawed'

Share:
VEGA Group Issues Short Report On GW Pharma; Expert Calls Thesis 'Flawed'
Related GWPH
The 2018 Farm Bill Vote: What You Need To Know
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
B. Riley FBR likes NASH players Viking Therapeutics and Galmed Pharma in premarket analyst action (Seeking Alpha)

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) stock more than doubled on positive Phase III data on its CBD-derived Epidiolex drug for treatment of Dravet syndrome. In a new report, The Vega Group says that the market has gotten way ahead of itself on the stock and that the valuations analysts are now placing on the drug are completely detached from reality.

“GW Pharmaceuticals falls short in every metric of how once should evaluate an early-to-mid stage drug development company; and yet, we believe WS analysts covering the equity have entirely neglected to price in both internal and external risk factors, a history of operational weakness and unfathomable levels of shareholder dilution,” the report reads.

Related Link: Patent Expert: It's Not Over For Gilead, Still Has Strong Defense Against Merck

Vega believes that the post-news spike now has GW’s stock trading more than 50 percent higher than its true value.

Industry expert Alan Brochstein tells Benzinga that the author of the Vega report makes several key mistakes in his analysis.

“He thinks that there will be competition from non-FDA approved manufacturers of CBD products, like Charlotte’s Web. This is not the case,” Brochstein explains. “If you read hit tweets, it appears that he isn’t especially qualified.”

Only time will tell if the market for Epidiolex and GW’s business execution will justify the stock’s huge surge.

Disclosure: the author holds no position in the stocks mentioned.

Latest Ratings for GWPH

DateFirmActionFromTo
Dec 2018OppenheimerInitiates Coverage OnPerform
Dec 2018Cantor FitzgeraldMaintainsOverweightOverweight
Nov 2018Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Short Ideas Analyst Ratings Movers Trading Ideas General Best of Benzinga

 

Related Articles (GWPH)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Yahoo Fails To Respond To Microsoft Financing Chatter

The Tesla Model 3 Launch: Elon Musk's Moment Of Truth?